[go: up one dir, main page]

WO2011064395A3 - Inhibitors and antagonists of calcium channels in the treatment of asthma - Google Patents

Inhibitors and antagonists of calcium channels in the treatment of asthma Download PDF

Info

Publication number
WO2011064395A3
WO2011064395A3 PCT/EP2010/068546 EP2010068546W WO2011064395A3 WO 2011064395 A3 WO2011064395 A3 WO 2011064395A3 EP 2010068546 W EP2010068546 W EP 2010068546W WO 2011064395 A3 WO2011064395 A3 WO 2011064395A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
calcium channels
asthma
antagonists
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/068546
Other languages
French (fr)
Other versions
WO2011064395A2 (en
Inventor
Lucette Pelletier
Jean-Charles Guery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of WO2011064395A2 publication Critical patent/WO2011064395A2/en
Publication of WO2011064395A3 publication Critical patent/WO2011064395A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an inhibitor of CACNA1C and/or CACNA1D gene expression for the treatment and/or the prevention of inflammatory diseases, preferably allergic diseases, and most preferably respiratory allergic diseases. The present invention also relates to a specific antagonist of at least one of the Cav1.2 and Cav1.3 subunits of voltage- dependent L- type calcium channels for the prevention and/or treatment of such inflammatory diseases.
PCT/EP2010/068546 2009-11-30 2010-11-30 Inhibitors and antagonists of calcium channels in the treatment of asthma Ceased WO2011064395A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09306160.4 2009-11-30
EP09306160 2009-11-30

Publications (2)

Publication Number Publication Date
WO2011064395A2 WO2011064395A2 (en) 2011-06-03
WO2011064395A3 true WO2011064395A3 (en) 2011-08-04

Family

ID=42077139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/068546 Ceased WO2011064395A2 (en) 2009-11-30 2010-11-30 Inhibitors and antagonists of calcium channels in the treatment of asthma

Country Status (1)

Country Link
WO (1) WO2011064395A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053310A1 (en) * 2000-01-18 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 3 expression
US20050074850A1 (en) * 2003-05-28 2005-04-07 Synta Pharmaceuticals Corp. Novel calcium channels and uses thereof
WO2006091795A2 (en) * 2005-02-25 2006-08-31 Board Of Regents, The University Of Texas System METHODS AND COMPOSITIONS INVOLVING EXPRESSION OF α1C SUBUNIT OF L-TYPE CALCIUM CHANNELS IN SMOOTH MUSCLE CELLS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053310A1 (en) * 2000-01-18 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 3 expression
US20050074850A1 (en) * 2003-05-28 2005-04-07 Synta Pharmaceuticals Corp. Novel calcium channels and uses thereof
WO2006091795A2 (en) * 2005-02-25 2006-08-31 Board Of Regents, The University Of Texas System METHODS AND COMPOSITIONS INVOLVING EXPRESSION OF α1C SUBUNIT OF L-TYPE CALCIUM CHANNELS IN SMOOTH MUSCLE CELLS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAS RIKU ET AL: "L-type calcium channel blockers exert an antiinflammatory effect by suppressing expression of plasminogen receptors on macrophages.", CIRCULATION RESEARCH 17 JUL 2009 LNKD- PUBMED:19520970, vol. 105, no. 2, 17 July 2009 (2009-07-17), pages 167 - 175, XP002578298, ISSN: 1524-4571 *
DJATA CABRAL MARILENA ET AL: "[A role for voltage-dependent related Ca2+ channels in calcium signaling of T lymphocytes]", MÉDECINE SCIENCES : M/S FEB 2007 LNKD- PUBMED:17291422, vol. 23, no. 2, February 2007 (2007-02-01), pages 136 - 138, XP008121567, ISSN: 0767-0974 *
RHEE SUNG W ET AL: "Vascular smooth muscle-specific knockdown of the noncardiac form of the L-type calcium channel by microRNA-based short hairpin RNA as a potential antihypertensive therapy.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS MAY 2009 LNKD- PUBMED:19244098, vol. 329, no. 2, May 2009 (2009-05-01), pages 775 - 782, XP008121679, ISSN: 1521-0103 *
WELLING A ET AL: "Inhibition of L-type Cav1.2 Ca2+ channels by 2,(4-morpholinyl)-8-phenyl-4it>H/it>-1-benzopyran-4-one (LY294002) and 2-(1-(3-dimethyl-aminopropyl)-5-methoxyindol-3-yl)-3-(1it>H/it>-indol 3-yl) maleimide (Go6983)", MOLECULAR PHARMACOLOGY, vol. 67, no. 2, February 2005 (2005-02-01), pages 541 - 544, XP002578296, ISSN: 0026-895X *

Also Published As

Publication number Publication date
WO2011064395A2 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
WO2010044981A3 (en) Benzoquinoline inhibitors of vesicular monoamine transporter 2
SMT201500213B (en) Some triazolopirazine, their compositions and methods of use
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
WO2010009091A3 (en) Anti-inflammatory and anti-allergy extracts from nettle
WO2008116920A3 (en) 17beta-hydroxysteroid-dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases
WO2010030983A3 (en) Pyrazole carboxamide inhibitors of factor xa
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
UA107089C2 (en) LACTOBACILLUS PLANTARUM Strains As Hypocholesterinemic Agents
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2009063215A3 (en) Use of crth2 antagonist compounds
IL197080A0 (en) Pyrimidone compounds as gsk-3 inhibitors
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
PL2106463T3 (en) METHOD AND EQUIPMENT FOR THE MANUFACTURE OF FLUORAMINE BIOCIDES
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
WO2011106248A3 (en) Trimethoxyphenyl inhibitors of tyrosine kinase
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
WO2010017368A3 (en) Methods and compositions for treating anxiety
AP2013006902A0 (en) e and their use as HSD 1 inhibitors A-S)-1-(1H-benzoimidazole-5-carbonyl)-2,3,4,4A,9,9Crystalline forms of hydrochloride salt of (4A-R,9A-hexahydro-1H-indeno[2,1-B]pyridine-6-carbonitril
TN2012000581A1 (en) Piperidinyl compound as a modulator of chemokine receptor activity
WO2011011420A3 (en) 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
WO2011123524A3 (en) Macrolide inhibitors of mtor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10787385

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10787385

Country of ref document: EP

Kind code of ref document: A2